V Espeli
Cost-effectiveness of nivolumab in the treatment of head and neck cancer
Hirschmann A, Lupatsch J, Schwenkglenks M, Panje C, Matter-Walstra K, Espeli V, Dedes K, Siano M, Swiss Group of Clinical Cancer Research (SAKK). Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral Oncol 2018; 87:104-110.
30.10.2018Cost-effectiveness of nivolumab in the treatment of head and neck cancer
30.10.2018Oral Oncol 2018; 87:104-110
Hirschmann A, Lupatsch J E, Schwenkglenks M, Panje Cédric, Matter-Walstra K, Espeli V, Dedes K J, Siano Marco, Swiss Group of Clinical Cancer Research (SAKK)
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Hottinger A, Bodmer A, Weber D, Schaller K, Mach N, Hundsberger T, Vargas M, Dunkel N, Squiban D, Espeli V, Ben Aissa A, Dietrich P. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 2018
09.01.2018Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
09.01.2018Br J Cancer 2018
Hottinger A F, Bodmer A, Weber D C, Schaller K, Mach N, Hundsberger Thomas, Vargas M I, Dunkel N, Squiban D, Espeli V, Ben Aissa A, Dietrich P-Y
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Hottinger A, Bodmer A, Weber D, Schaller K, Mach N, Hundsberger T, Vargas M, Dunkel N, Squiban D, Espeli V, Aissa A, Dietrich P. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 2014; 110:2655-2661.
01.05.2014Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
01.05.2014Br J Cancer 2014; 110:2655-2661
Hottinger A F, Bodmer A, Weber D C, Schaller K, Mach N, Hundsberger Thomas, Vargas M I, Dunkel N, Squiban D, Espeli V, Aissa A B, Dietrich P-Y